Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Alcobra Ltd. (Nasdaq: ADHD)

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. *

 

Period Start 2014-10-10 existent
Period End 2017-09-27 merger announced
  Group Arcturus Therapeutics (Group)
  Today Arcturus Therapeutics Ltd. (Nasdaq: ARCT)
  Successor Arcturus Therapeutics Ltd. (Nasdaq: ARCT)
Products Industry MDX (Alcobra Ltd)
  Industry 2 drug development
     
Region Region Tel Aviv
  Country Israel
  Street 132 Derech Menachem Begin
Azrieli Triangle Building, 39th Floor
  City 6701101 Tel Aviv
    Address record changed: 2017-06-26
     
Basic data Employees n. a.
  Currency USD
  Profit -24,609,000 (2016-12-31)
  Cash 2,304,000 (2016-12-31)
     
    * Document for �About Section�: Alcobra Ltd.. (1/9/15). "Press Release: Alcobra Ltd. Prices Public Offering of Ordinary Shares". Tel Aviv.
     
   
Record changed: 2018-10-31

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Arcturus Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top